Tribio Anti-Human FLT3 & AXL & CD40 Bispecific Antibody (TBS10421)

Description

Description: Tribio FLT3 & AXL & CD40 Bispecific Antibody is a modified antibody that can engage FLT3 and AXL on target cells while also binding CD40 on immune cells. It is designed for cancer immunology research to explore combined targeting of tumor-associated receptors and immune activation pathways, promoting immune cell activation and anti-tumor responses. It is commonly used in studies of hematologic malignancies and solid tumors involving FLT3/AXL signaling.

Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Species reactivity: Human

Host species: Human

Target: FLT3, Stem cell tyrosine kinase 1, Fetal liver kinase-2, STK-1, STK1, FLK2, CD135, Receptor-type tyrosine-protein kinase FLT3, Fms-like tyrosine kinase 3, FL cytokine receptor, FLK-2, FLT-3, UFO, AXL oncogene, Tyrosine-protein kinase receptor UFO, AXL, Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Isotype: IgG1

Accession/UniProt: P36888 & P30530 & P25942

Concentration: 3 mg/ml

Purity: >95%

Formulation: Liquid

Storage buffer: 0.01M PBS, pH 7.4

Purification: Protein A/G purified from cell culture supernatant.

Clonality: Monoclonal

Storage: Avoid repeated freeze-thaw cycles. -20°C for 12 months; -80°C for long-term storage.

Research use only.

Additional information